Knockdown of the interleukin-6 receptor alpha chain of dendritic cell vaccines enhances the therapeutic potential against IL-6 producing tumors
- Authors
- Hwang, Wonchan; Jung, Keunok; Jeon, Youkyoung; Yun, Shik; Kim, Tae Woo; Choi, Inhak
- Issue Date
- 10-12월-2010
- Publisher
- ELSEVIER SCI LTD
- Keywords
- Dendritic cell vaccine; Knockdown; IL-6 receptor
- Citation
- VACCINE, v.29, no.1, pp.34 - 44
- Indexed
- SCIE
SCOPUS
- Journal Title
- VACCINE
- Volume
- 29
- Number
- 1
- Start Page
- 34
- End Page
- 44
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/115123
- DOI
- 10.1016/j.vaccine.2010.10.027
- ISSN
- 0264-410X
- Abstract
- Tumor microenvironment has emerged as one of the major obstacles against the clinical efficacy of dendritic cell (DC) vaccines. Tumor-derived IL-6 may inhibit the differentiation of hematopoietic progenitor cells into DCs and suppress DC maturation, rendering DCs tolerogenic. We hypothesized that silencing the IL-6 receptor alpha chain (IL-6R alpha) would restore the functional competence of DC vaccines in mice with an IL-6-producing TC-1 tumor, and eventually give rise to protective immunity. We found that the IL-6R alpha knockdown-DC vaccine significantly enhanced the frequency of tumor-specific CD8(+) CTLs-producing effector molecules such as IFN-gamma, TNF-alpha, FasL, perforin, and granzyme B, and generated more CD8(+) memory T cells, leading to the substantially prolonged survival of TC-1 tumor-bearing mice. (C) 2010 Elsevier Ltd. All rights reserved.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Graduate School > Department of Biomedical Sciences > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.